Zai Lab Ltd (ZLAB) stock
ZLABNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 7/30420% above fair value
$23.53+0.06 (+0.26%)
Close on Nov 17, 2026Market cap $3.65BP/E –Yield –
Zai Lab price to sales ratio
The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.
Zai Lab's price to sales ratio was 6.6× on Nov 11, 2026, against 5.1× a year earlier. Over the last 5 years it ranged from 4.2× to 52.0×, with a median of 9.1×.
Price to Sales Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Nov 11, 2026 | 6.6× | +2.2 |
| 2025 | Dec 31, 2025 | 4.4× | −2.8 |
| 2024 | Dec 31, 2024 | 7.2× | −2.8 |
| 2023 | Dec 29, 2023 | 10.1× | −5.0 |
| 2022 | Dec 30, 2022 | 15.0× | −37.0 |
| 2021 | Dec 31, 2021 | 52.0× | −211.2 |
| 2020 | Dec 31, 2020 | 263.2× | – |
See a number that looks wrong?